Form 4: Rigel Pharmaceuticals Executive Acquires Shares and Options

Raymond J. Furey, an executive at Rigel Pharmaceuticals, acquired shares and stock options as part of a compensation package.

Summary

• Raymond J. Furey, an EVP, GC, CCO & Corp Sec at Rigel Pharmaceuticals, reported acquiring 19,717 shares of common stock and 14,788 stock options on January 29, 2025.
• The shares were acquired through the vesting of a Restricted Stock Unit award, which will vest annually over three years starting February 10, 2026.
• The stock options vest monthly over three years from January 29, 2025, contingent on continuous service.
• The reported transactions also include 500 shares acquired under the company's stock purchase plan.
• The total number of shares beneficially owned by Furey after the transaction is 41,617, which includes adjustments for a one-for-ten reverse stock split effective June 27, 2024.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally positive for aligning management with shareholder interests. There are no negative implications.

Positives

• The acquisition of shares and options aligns the executive's interests with the company's performance.
• The vesting schedule of the awards encourages long-term commitment from the executive.

Future Outlook

The executive's stock options will vest monthly over three years, and the restricted stock units will vest annually over three years, both contingent on continued service.

Industry Context

This is a standard SEC Form 4 filing, which is common for executives receiving stock-based compensation in publicly traded companies. It reflects typical practices for aligning management interests with shareholder value.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the pharmaceutical industry, used to attract and retain key talent.
• The vesting schedules for both the stock options and restricted stock units are typical for executive compensation packages.
• Companies like Gilead Sciences, Amgen, and Biogen also use similar stock-based compensation plans for their executives.

Stakeholder Impact

• The stock-based compensation aligns the executive's interests with those of shareholders.
• The vesting schedule encourages long-term commitment from the executive, which can benefit the company and its stakeholders.

Next Steps

• The executive will continue to vest in the stock options and restricted stock units over the next three years, contingent on continued service.

Key Dates

Keywords

Rigel Pharmaceuticals, stock options, restricted stock units, insider trading, executive compensation, share acquisition, Form 4